“The scientists at Novo Nordisk deserve great credit for developing these drugs that have the potential to be a game changer for millions of Americans struggling with type 2 diabetes and obesity.
As important as these drugs are, they will not do any good for the millions of patients who cannot afford them,” Sanders, chair of the Senate Committee on Health, Education, Labor and Pensions, wrote Wednesday in a letter to the drugmaker’s CEO.
Ozempic is approved by the US Food and Drug Administration to treat diabetes and Wegovy to help certain people lose weight or lower their risk of cardiovascular disease.
The drugmaker told CNN in February that it increases the list prices of some medications each year based on changes in the health care system, inflation and market conditions.
In addition, many drug manufacturers, including Novo Nordisk, offer savings cards and patient assistance programs that can reduce certain people’s out-of-pocket costs.
Ozempic is also proving costly for the federal government, while Wegovy’s recent approval to reduce the risk of heart attacks and strokes is expected to add to the tab.
The original article contains 611 words, the summary contains 180 words. Saved 71%. I’m a bot and I’m open source!
This is the best summary I could come up with:
“The scientists at Novo Nordisk deserve great credit for developing these drugs that have the potential to be a game changer for millions of Americans struggling with type 2 diabetes and obesity.
As important as these drugs are, they will not do any good for the millions of patients who cannot afford them,” Sanders, chair of the Senate Committee on Health, Education, Labor and Pensions, wrote Wednesday in a letter to the drugmaker’s CEO.
Ozempic is approved by the US Food and Drug Administration to treat diabetes and Wegovy to help certain people lose weight or lower their risk of cardiovascular disease.
The drugmaker told CNN in February that it increases the list prices of some medications each year based on changes in the health care system, inflation and market conditions.
In addition, many drug manufacturers, including Novo Nordisk, offer savings cards and patient assistance programs that can reduce certain people’s out-of-pocket costs.
Ozempic is also proving costly for the federal government, while Wegovy’s recent approval to reduce the risk of heart attacks and strokes is expected to add to the tab.
The original article contains 611 words, the summary contains 180 words. Saved 71%. I’m a bot and I’m open source!